Exeliom Biosciences is a clinical-stage biotechnology company developing next-generation immunotherapies in immuno-oncology and immuno-inflammation. EXL01 – our lead drug candidate - is a first-in-class oral drug with a novel mechanism of action that demonstrates enhanced activation of key regulators of the innate immune system. Thanks to a robust and scalable manufacturing process EXL01 is being evaluated in 6 clinical trials, including: - A phase I trial, as monotherapy, in Crohn's (recruitment completed), - Three phase II trials, as combination therapy, in immuno-oncology in combination with immune checkpoint inhibitors (2 ongoing and 1 to start end of 2024), - A phase I/II trial in the prevention of recurrent C. difficile infection (ongoing). - An additional Phase II trial, as monotherapy and combination therapy, in postoperative Crohn's disease is due to start late 2024.